Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells $264,818.40 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa sold 11,464 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $23.10, for a total value of $264,818.40. Following the completion of the sale, the chief financial officer now owns 23,382 shares of the company’s stock, valued at approximately $540,124.20. The trade was a 32.90 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Mark Ragosa also recently made the following trade(s):

• On Wednesday, March 19th, Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $23.10, for a total value of $205,104.90.
• On Wednesday, March 12th, Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $22.25, for a total value of $809,277.00.

Kiniksa Pharmaceuticals Price Performance

NASDAQ KNSA opened at $23.81 on Friday. The stock has a market capitalization of $1.73 billion, a PE ratio of -170.06 and a beta of 0.48. The business has a 50 day simple moving average of $20.23 and a two-hundred day simple moving average of $22.09. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $16.56 and a 1-year high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.35 earnings per share. On average, analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $1,192,000. JPMorgan Chase & Co. bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $4,997,000. Parkman Healthcare Partners LLC lifted its stake in shares of Kiniksa Pharmaceuticals by 16.7% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock worth $18,874,000 after acquiring an additional 108,102 shares during the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $675,000. Finally, SG Americas Securities LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the 4th quarter worth approximately $355,000. 53.95% of the stock is owned by institutional investors.

Analyst Ratings Changes

KNSA has been the subject of several research analyst reports. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a “buy” rating and a $40.00 target price for the company. Wedbush reiterated an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $37.17.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.